14 Analysts Have This to Say About Apellis Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Apellis Pharmaceuticals (NASDAQ:APLS) received ratings from 14 analysts in the last quarter, with 9 bullish, 2 somewhat bullish, and 3 indifferent. No analysts were somewhat bearish or bearish. The average 12-month price target for APLS is $71.36, with a high of $93.00 and a low of $42.00. This target has increased by 22.34% from the previous average of $58.33. Analysts rate stocks based on research and forecasts, and these ratings can guide investors' decisions.

December 05, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Apellis Pharmaceuticals has received a majority of bullish ratings from analysts, with an average price target of $71.36, representing a significant increase from the previous target. This positive sentiment could influence the stock price positively in the short term.
The increase in the average price target and the predominantly bullish ratings from analysts are strong indicators of a positive sentiment towards Apellis Pharmaceuticals. This could lead to increased investor confidence and a potential rise in the stock price in the short term. However, as analyst ratings are forecasts and not guarantees, the confidence level is not at the maximum.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100